Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | EPX | P11678 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22083543 | 0.81 | DAO (0.43) | CYP3A4MEN1KMT2ACALM1MET | |
| SCHEMBL27629487 | 0.78 | PARP1 (0.43) | MPOTPOCYP3A4EPXMEN1 | |
| SCHEMBL29339712 | 0.78 | TP53 (0.40) | MEN1KMT2ACALM1MET | |
| SCHEMBL4857853 | 0.77 | BCL2 (0.48) | CYP3A4MEN1KMT2ACALM1MET | |
| SCHEMBL16148679 | 0.77 | TYMP (0.42) | CYP3A4MEN1KMT2ACALM1MET | |
| SCHEMBL8993116 | 0.77 | LTA4H (0.45) | MPOCYP3A4CALM1LTB4RAOC3 | |
| SCHEMBL14720321 | 0.75 | GPR84 (0.38) | MPOMEN1KMT2A | |
| SCHEMBL3318684 | 0.74 | KMT2A (0.40) | MPOTPOCYP3A4EPXMEN1 | |
| SCHEMBL7421266 | 0.74 | ALDH1A1 (0.40) | MPOTPOCYP3A4EPXMEN1 | |
| SCHEMBL7428528 | 0.74 | BCL2 (0.46) | CYP3A4MEN1KMT2ACALM1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2121619-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC Immune S.A. (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | MPO 3124/4885TPO 4832/4885CYP3A4 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.